Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK08 Bexagliflozin
D10865 Bexagliflozin (USAN) <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhbitor
Bexagliflozin
D10865 Bexagliflozin (USAN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
D10865 Bexagliflozin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D10865 Bexagliflozin
DG02924 UGT substrate
DG03188 UGT1A9 substrate
D10865 Bexagliflozin
Drug classes [BR:br08332]
Antidiabetic agent
DG01794 SGLT2 inhibitor
D10865 Bexagliflozin
DG02044 Hypoglycemic agent
D10865 Bexagliflozin
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC5
SLC5A2 (SGLT2)
D10865 Bexagliflozin (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10865
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10865
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10865